Isoflavones, abundant in soybeans, chickpeas, lentils, and other legumes, have been shown to exhibit a variety of potential activities, including anti-inflammatory and neuroprotective properties [61]

Customers tell us they want peace of mind so that if a consumer has their beverage across multiple day parts, they will have a large margin before hitting tolerance levels. Why beverage brands need to brace themselves The thirst for GLP-1 medication only looks set to increase among consumers with the launch of unfussy, non-injectable formats A pill version of the appetite-suppressing drug, Wegovy, was unveiled by pharma giant Novo Nordisk in January Eli Lilly & Co is preparing to debut its own oral version, Orforglipron, post-FDA approval later this year The total GLP-1 pill market is forecast to leap from $3.2bn in 2025 to 34.3 bn in 2031, a CAGR of 48.4% (GlobalData) (Source GlobalData) GLP-1 drink NPD outside the box Although, its not just traditional food and beverage companies developing tailored NPD

But beneath the hype and fear is a simple story: these drugs target a core metabolic signaling pathway that influences cardiovascular health, inflammation, cognition, kidney function, and long-term resilience
Through these receptors, GLP-1 helps regulate blood glucose, appetite, and body weight
Facebook Email or phone Password Forgot account
Robinson M, Davidson A